Department of Clinical & Chemical Pathology Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Department of Internal Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Egypt J Immunol. 2020 Jun;27(2):81-92.
Modulation of the immune inflammatory system has been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN); nevertheless, many of the underlying mechanisms are still unknown. A possible role of micro-RNA 152-3p in T2DM and DN has been suggested due to its immunomodulatory effect on the innate immunity. This case control study aimed, first, to determine the possible role of micro-RNA 152-3p in the pathogenesis of T2DM and DN by evaluating its serum expression in T2DM and DN patients. Second, to assess the performance of serum micro-RNAs 16 and 24 as endogenous control in TaqMan assays of micro-RNA analysis by real time PCR in such disease. Quantification of the expression of micro-RNA 152-3p by qRT-PCR was performed using serum of 70 subjects enrolled in this study and grouped into 20 apparently healthy non-diabetic participants (control group), 15 patients with T2DM without nephropathy (DM group) and 35 diabetic patients with nephropathy (DN group). In diabetic patients with nephropathy (DN) (P<0.001), or without nephropathy (DM) (P 0.004), the expression of micro-RNA 152-3p demonstrated a significant elevation in comparison to the controls. Also, the level of micro-RNA 152-3p showed a positive correlation with HbA1c and the duration of diabetes mellitus. The severity of nephropathy as evaluated by markers of renal disease progression; estimated (e)GFR and albumin/creatinine ratio (ACR) revealed a significant correlation with the level of micro-RNA 152-3p. In the same context, serum level of micro-RNA 152-3p was elevated in diabetics with advanced stage of nephropathy (macroalbuminuria) versus the rest of diabetics (without albuminuria and with microalbuminuria). Two one sided T procedure provided a strong statistical support for equivalence of both micro-RNA s 16 and 24. In conclusion, such findings may indicate a pathologic role of micro-RNA 152-3p in Type 2 diabetes mellitus and in the progression of diabetic nephropathy.
调节免疫炎症系统已被认为与 2 型糖尿病（T2DM）和糖尿病肾病（DN）的发病机制有关；然而，许多潜在的机制仍不清楚。由于 microRNA 152-3p 对先天免疫具有免疫调节作用，因此它在 T2DM 和 DN 中的可能作用已被提出。本病例对照研究旨在通过评估 T2DM 和 DN 患者血清中 microRNA 152-3p 的表达，首先确定其在 T2DM 和 DN 发病机制中的可能作用。其次，评估血清 microRNAs 16 和 24 作为实时 PCR TaqMan 分析中 microRNA 分析内源性对照的性能。通过 qRT-PCR 对 70 名入组研究的受试者的血清进行 microRNA 152-3p 的表达定量，并将其分为 20 名明显健康的非糖尿病参与者（对照组）、15 名无肾病的 2 型糖尿病患者（DM 组）和 35 名有肾病的糖尿病患者（DN 组）。在有肾病的糖尿病患者（DN）（P<0.001）或无肾病的糖尿病患者（DM）（P<0.004）中，与对照组相比，microRNA 152-3p 的表达显著升高。此外，microRNA 152-3p 的水平与 HbA1c 和糖尿病的持续时间呈正相关。通过评估肾脏疾病进展的标志物（估计的[e]GFR 和白蛋白/肌酐比值[ACR]）评估的肾病严重程度与 microRNA 152-3p 的水平呈显著相关性。在同样的情况下，处于肾病晚期（大量蛋白尿）的糖尿病患者的血清 microRNA 152-3p 水平高于其余糖尿病患者（无蛋白尿和微量白蛋白尿）。单边 T 检验为 microRNA s 16 和 24 的等效性提供了强有力的统计支持。总之，这些发现可能表明 microRNA 152-3p 在 2 型糖尿病和糖尿病肾病进展中具有病理作用。
